For example, the relevance of CD146 as a marker for the identification of a subpopulation of cEPC with particular propensity for a potential proangiogenic therapy and for the monitoring of vascular injury/regeneration processes in selected clinical conditions (i.e., myocardial infarction) has been suggested [76]. The gene discussed is MCAM; the disease is myocardial infarction.